33
Participants
Start Date
January 31, 2025
Primary Completion Date
May 31, 2026
Study Completion Date
December 31, 2026
TQB3616 capsule+Fulvestrant Injection
TQB3616 capsule is a CDK2/4/6 inhibitor and Fulvestrant injection is an anti-estrogen medication, and its pharmacological mechanism mainly exerts its therapeutic effect by inhibiting the action of aromatase.
Xingtai People's Hospital, Xingtai
Liaoning Cancer Hospital, Shenyang
Harbin Medical University Cancer Hostipal, Harbin
Jiangsu Provincial People's Hospital, Nanjing
Hai'an People's Hospital, Nantong
The First Affilliated Hospital of Bengbu Medical University, Bengbu
Cancer Hospital of Shandong First Medical University(Shandong Cancer Institute, Shandong Cancer Hospital), Jinan
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Hunan Cancer Hospital, Changsha
Luohe Central Hospital, Luohe
Jiangmen Central Hospital, Jiangmen
The Affiliated Hospital of Southwest Medical University, Luzhou
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY